Innate Pharma Q3 2026: Cash Rebuilt to €96.8M, Runway to Q1 2028; CFO to Depart
IPHA sits 25% above its 52-week low of $1.17 on light trading volume (0.1× avg).
Summary
Innate Pharma ended Q3 2026 with €96.8 million in cash and financial assets, enough to fund operations until the end of Q1 2028, after the Sobi upfront and August placement. The CFO will step down December 31, 2026, and IPH4502 Phase 1 data lands November 18.
Key Events · Earnings and Guidance · IPHA
-
Cash Rebuilt to €96.8M
Cash, cash equivalents and financial assets reached €96.8 million as of September 30, 2026, including the $75 million Sobi upfront and the €30 million August private placement, against financial liabilities of €16.2 million.
-
Runway Extended to Q1 2028
The company anticipates a cash horizon until the end of Q1 2028, a sharp reversal from the €21.4 million cash and negative €40.5 million equity reported at H1 2026.
-
CFO to Depart December 31
Frédéric Lombard will step down as Chief Financial Officer on December 31, 2026; a search for a replacement has been initiated.
-
IPH4502 Data Due November 18
Phase 1 dose-escalation data from the 76-patient IPH4502-101 study will be presented at ENA 2026 on November 18, followed by a hybrid investor event.
Analysis · IPHA · Life Sciences
The balance sheet has been transformed since the H1 report. Cash, cash equivalents and financial assets stood at €96.8 million on September 30, 2026 — up from the €21.4 million and negative €40.5 million equity reported at H1 — after the $75 million Sobi upfront and the €30 million August private placement. That funds operations until the end of Q1 2028, removing the near-term financing overhang that dominated the prior quarter. Against that backdrop, the CFO's departure on December 31, 2026 introduces execution risk just as the company prepares first patient dosing in the Phase 3 TELLOMAK-3 study in Q1 2027 and an FDA accelerated approval filing in Sézary syndrome in H2 2027. The IPH4502 Phase 1 dose-escalation data on November 18 is the next hard readout, and the AstraZeneca-led PACIFIC-9 readout has slipped to H1 2027 from H2 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IPHA was trading at $1.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.3M. The 52-week trading range was $1.17 to $2.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.